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Abstract
Loop diuretics (LD) may affect bone health by inhibiting renal calcium reuptake. However, whether vitamin D status and die-
tary calcium intake modify the association between LD and bone outcome is unclear. Therefore, this study aimed to evaluate 
whether vitamin D level or calcium intake modify the association between LD and various indices of bone health including 
bone mineral density (BMD) and Trabecular Bone Score (TBS). From The Rotterdam Study, a prospective population-based 
cohort study, we used data from 6990 participants aged > 45 year with a DXA scan (2002–2008), 6908 participants with 
femoral neck (FN)-BMD, 6677 participants with lumbar spine (LS)-BMD and 6476 participants with LS-TBS measurements. 
Use of LD was available from pharmacy dispensing records. Vitamin D (25(OH)D) level was measured in serum, and dietary 
calcium intake was measured with a validated food frequency questionnaire. Almost eight percent of the participants used 
LD. The association between LD (past-users compared to never-users) and LS-TBS was significantly different by 25(OH)
D concentrations (P for interaction = 0.04). A significantly lower LS-TBS among LD past-users was observed for 25(OH)
D ≥ 50 nmol/l compared to ≤ 20 and 20–50 nmol/l (β = − 0.036, 95% CI − 0.060; − 0.013 vs. β = − 0.012, 95% CI − 0.036; 
0.013 and β = − 0.031, 95% CI − 0.096; 0.034, respectively). However, no other significant effect modification by 25(OH)D 
and dietary calcium intake was found in the associations between LD use and bone health outcomes (P-interaction > 0.13). 
This study suggests that the association between LD use and indices of bone health is not consistently modified by vitamin 
D or dietary calcium intake.
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Introduction
In the past decade, recognition of the importance of food 
and drug interactions has been growing in clinical practice 
[1]. Especially in older people, however, more knowledge 
is needed because of the frequent use of medications and 
polypharmacy and higher risk of poor nutritional status 
[2]. Food-drug interactions may be relevant in older peo-
ple using loop diuretics (LD). Diuretics are frequently 
prescribed in the treatment of heart failure and hyperten-
sion [3, 4], and they have been shown to influence calcium 
homeostasis and bone metabolism.
Thiazide diuretics have shown to have a protective 
effect in preserving bone mass and in decreasing the risk 
of fractures [5]. Yet, these effects have been shown to vary 
in relation to dosage, duration of treatment and do not last 
long after discontinuation of treatment [6–8]. In contrast, 
few studies have been carried out assessing the effect of 
loop diuretics (LD) on skeletal health. Some studies sug-
gest that LD can have a negative impact on bone turno-
ver by increasing urinary calcium excretion [9, 11–13], 
whereas others show no association between LD use and 
bone health on long-term use [6–13].
These conflicting findings may be the result of differences 
in calcium intake and vitamin D levels across the studied 
population, considering that bone mineral deposition/forma-
tion and bone resorption can be relatively normal as long 
as serum calcium and phosphate and calciotropic hormone 
levels like vitamin D and parathyroid hormone (PTH) are 
normal [14]. Vitamin D has a major role in calcium homeo-
stasis through three mechanisms: (I) increased intestinal 
absorption of calcium, (II) reduced renal excretion of cal-
cium by stimulating resorption of the distal tubules and (III) 
deposition and mobilization of calcium from bones [15]. An 
inverse association between LD use and serum 25(OH)D 
level has been reported before [16]. LD users have a lower 
concentration of 25(OH)D than non-users [17]. As a result, 
vitamin D deficiency may amplify any potential adverse 
effects of LD on bone health due to increased urinary cal-
cium losses. Also, the use of LD may be harmful for bone 
health through increased plasma PTH and 1.25(OH)2D lev-
els as a result of increased renal calcium losses [13]. Higher 
calcium loss may increase bone turnover resulting in a 
negative calcium balance. Furthermore, in case of very low 
external calcium supply from diet or supplementation, high 
levels of 1.25(OH)2D3 mobilize the bone calcium reservoir 
for serum calcium homeostasis at the (temporary) expense 
of bone mass and strength [18]. Accordingly, in people with 
a low calcium intake, the effect of LD on bone loss and 
increased fracture risk may be enhanced [10].
Therefore, in view of the frequent use of LD and a high 
prevalence of osteopenia and osteoporosis in the ageing 
population, in combination with a higher risk of malnu-
trition and vitamin D deficiency in older individuals, it is 
important to evaluate whether vitamin D level or calcium 
intake may modify the association between loop diuretics 
and various indices of bone health including bone mineral 
density (BMD) and trabecular bone score (TBS) in elderly 
population.
Materials and Methods
Study Population
This study was embedded in the first three cohorts of 
The Rotterdam Study (RS-I, RS-II and RS-III), an ongo-
ing, population-based cohort study in Ommoord, a suburb 
of Rotterdam, the Netherlands [19]. Since January 1990, 
participants of 55 years and over were recruited for RS-I 
(N = 7983). In 2000, the study was extended to 3011 partici-
pants (RS-II). Later in 2006, the study was extended with a 
third cohort of participants of 45 years and older (RS-III). 
Overall response for all three cycles at baseline was 72% 
(14,926 of 20,744) [19]. Participants were interviewed at 
home by a trained research assistant, after which they were 
invited for a physical examination and dietary assessment 
at the research centre. More details on the main objectives, 
design and diagram of examination cycles of the Rotterdam 
Study (RS) have been published elsewhere [19]. Because of 
a possible persisting effect on bone, users of bisphospho-
nates were excluded from the study. For the current analy-
sis, 6908 participants with data available for femoral neck 
(FN)-BMD, 6677 participants with lumbar spine (LS)-BMD 
and 6476 participants with LS-TBS were included from the 
fourth examination of the first cohort (RS-I-4, 2002–2004), 
the second examination of the second cohort (RS-II-2, 
2004–2005) and the first examination of the third cohort 
(RS-III-1, 2006-2008) (Fig. 1).
Dietary Intake and Serum 25(OHD) Level
Dietary data were collected at baseline (between 1989 and 
1993 in RS-I-1, between 2000 and 2001 in RS-II-1 and 
between 2006 and 2008 in RS-III-1) using a validated semi-
quantitative Food Frequency Questionnaire (FFQ) managed 
by a trained dietician, at the study centre [20, 21]. For RS-I-1 
and RS-II-1, a two-stage 170-items FFQ was used (during 
first stage, participants mentioned on 170 food item, which 
foods they consumed at least twice a month in the preceding 
year, and in the second stage, dietician identified how often 
and in which amounts the foods were consumed). For RS-
III-1, a one-stage 389-items FFQ was used. Dietary intake 
of nutrients (incl. total energy and dietary calcium intake) 
was determined using the Dutch Food Composition Tables 
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(NEVO) from 1993, 2001 and 2006, using standardized por-
tion sizes [20, 22]. Intake of calcium was adjusted for energy 
corresponding to the residual method [23]. Serum 25(OH)
D was measured in the blood collected at the same time as 
dietary data, between 1990 and 2008 using electrochemi-
luminescence immunoassay (COBAS, Roche Diagnostics 
GmbH). The sensitivity of the test was 10 nmol/L, the range 
of serum 25(OH)D concentrations was from 7.5 nmol/L to 
175 nmol/L, the within-run accuracy was less than 7.8%, and 
the intermediate precision accuracy was less than 13.1% [24, 
25]. Vitamin D deficiency was defined as a serum 25(OH)D 
level ≤ 50 nmol/L according to the current recommendations 
for older adults aged > 70 years by the Institute of Medicine 
and the Dutch Health Council [26]. In addition, we used 
also a vitamin D deficiency threshold < 20 nmol/L in our 
analysis and showed the stratification analysis in categories 
of ≤ 20 nmol/L, between 20–50 nmol/L and ≥ 50 nmol/L.
Loop Diuretics
As of 1st January 1991, pharmacy records of prescriptions 
were collected via all pharmacies in the Ommoord region 
with details on product name, ATC code, number of tablets/
capsules in each prescription, and prescribed daily number 
[27]. LD use (ATC code C03C) was determined from base-
line to the date of the DXA scan [19] and defined in three 
different categories: current-users, past-users and never-
users. Current-users were defined when the participant had a 
drug exposure period between the date of the DXA scan and 
120 days prior to the performed DXA scan. Past-users were 
defined when the participant had a drug exposure period 
more than 120 days prior to the performed DXA scan. In 
addition, if the participants had no drug exposure from base-
line till the DXA scan, the participants were considered as 
never-users. The duration of LD use among current-users 
was categorized into 1–120 days, 120–365 days and more 
than 365 days. Never-use of LD was used as the reference 
category.
Assessment of Co‑variables
Co-variables related to lifestyle, body composition and 
socioeconomic status (SES) were included. Weight (kg) 
and height (cm) were measured at study entry. BMI was 
calculated as weight divided by height squared (kg/m2). Dur-
ing home interviews physical activity (PA) was assessed by 
means of the Zutphen Physical Activity Questionnaire [28]. 
Metabolic equivalent of tasks were calculated (MET hours/
week) according to time spent in categories of light, moder-
ate and vigorous activity [28]. Socioeconomic status vari-
ables (i.e. educational level and income level), smoking (yes/
no), pack-years, use of alcohol, prevalence of coronary heart 
diseases (CHD), stroke and diabetes mellitus (DM) were 
assessed by home interview. Also the use of bisphosphonates 
was determined using pharmacy dispensing records in the 
same way as the use of LD. Serum calcium, magnesium and 
sodium were measured in blood samples by the Department 
of Clinical Chemistry of the Erasmus Medical Center using 
the Roche/Hitachi cobas c501 analyzer (Roche Diagnostics, 
Indianapolis, IN, USA).
Outcome Assessment
Femoral neck and lumbar spine BMD was measured at RS-I-
4, RS-II-2 and RS-III-1 (between 2002 and 2008) by dual-
energy X-ray absorptiometry (DXA) using a ProdigyTM 
fan-beam densitometer (GE Lunar Corp, Madison, WI, USA 
for all participants [19]. The DXA-derived trabecular bone 
score (TBS), which is measured in the Lumbar Spine (LS-
TBS), is a grey-level texture measurement that correlates 
with 3D parameters of bone microarchitecture, connectivity 
density, trabecular separation and trabecular number [29]. 
LS-TBS predicts future fractures (all type) independent of 
areal BMD [30]. Moreover, recent studies have shown that 
LS-TBS may be an applicable measure of trabecular bone 
integrity to study in regard to lifestyle factors that are adapt-
able, such as a dietary intake [31, 32]. LS-TBS was derived 
from the same lumbar DXA scans that BMD was obtained 
from and it was analysed using TBS iNsight software (ver-
sion 1.9; Medimaps, Geneva, Switzerland) at the Bone Dis-
ease Unit of the University of Lausanne (Lausanne, Swit-
zerland). LS-TBS was calculated for a subgroup of RS-I-4, 
RS-II-2 and RS-III-1 and represents the mean value of the 
individual vertebral measurements from L1 to L4. Subjects 
with a BMI higher than 37 kg/m2 were excluded from the 
study since LS-TBS measurements in morbidly obese per-
sons are not accurate. Furthermore, the LS-TBS was stand-
ardized according to sex using the residual method, due to 
RS-I-4
2002-2004
N=3,550
RS-II-2
2004-2005
N=2,468
RS-III-1
2006-2008
N=3,932
FN-BMD
N=6,908
LS-BMD
N=6,677
LS-TBS
N=6,476
DXA-data available
N=6,990
No DXA data 
available N=2,960
Fig. 1  Flow-chart of sub-cohorts included in the study
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technical differences between LS-TBS across sexes. The 
method of LS-TBS calculation has been described in detail 
elsewhere [32].
Statistical Analyses
First, for all variables normal distribution was examined by 
visual check of histograms. When necessary, data were log 
transformed. Linear regression analysis (cross-sectional) 
was used to assess the association between LD use (past-, 
current-use and the duration of 1–120 days, 120–365 days 
and > 365 days) and FN-BMD, LS-BMD and LS-TBS. All 
the analyses were adjusted for age and sex and cohort (model 
1). Thereafter, the co-variables were added additionally to 
model 2, based on literature relevance as well as principles 
of causal inference combined with the change-in-effect-cri-
terion of ≥ 10% [33, 34]. Potential confounders were BMI, 
smoking (pack-years), alcohol intake (g/day), SES (educa-
tion and job), total physical activity (MET hours/week) and 
comorbidities (prevalence of CHD, stroke and DM). For the 
analysis of the duration (continuous), the model was addi-
tionally adjusted for the past-users. An earlier study showed 
that in subjects with osteopenia/normal BMD levels, TBS is 
significantly associated with vertebral fractures [35]. Even 
though BMD and TBS are correlated, they present different 
aspects of bone health [35]. For that reason, as sensitivity 
analyses, we wanted to assess how the association between 
LD and BMD may depend on measures of bone architecture 
(i.e. TBS) and how a potential association between LD and 
TBS is dependent on BMD. So, the association between LD 
and FN-BMD and LS-BMD was additionally adjusted for 
LS-TBS and vice versa (model 3). In addition, in all analy-
ses, sensitivity analyses were performed with additional 
adjustment for serum vitamin D, season of blood collection 
of vitamin D [winter (September till end of February) and 
summer (March till end of August)], serum calcium, mag-
nesium and sodium concentrations.
To assess whether effect modification by serum 25(OHD) 
level or dietary calcium intake was present in the association 
of LD (ever-use) on FN-BMD, LS-BMD and LS-TBS, we 
evaluated the effect modification by serum 25(OH)D level 
and energy adjusted dietary calcium intake on FN-BMD, 
LS-BMD and LS-TBS in model 2 (P for interaction < 0.10), 
since the beta did not changed after additional adjustment 
in model 3. Thereafter, we stratified the analyses of LD 
use (LD never-use, current-use and past-use with never-
use as reference category) and bone outcomes according 
to serum 25(OH)D level, in subsequent categories of ≤ 20, 
between 20–50 and ≥ 50 nmol/L) and energy adjusted die-
tary intake of calcium in following categories: ≤ 950 mg/
day, 950–1200 mg/day and ≥ 1200 mg/day. The association 
between LD and LS-TBS, LS-BMD and FN-BMD was also 
evaluated by sex through effect modification.
To account for missing data in co-variables (varied from 
1.6 to 66.8%), we used a multiple imputation approach 
(n = 10 imputations, 10 iterations). Briefly, as described by 
Sterne et al, multiple imputation is created on the correla-
tion between each variable and missing values with other 
participant characteristics [36]. Linear regression analyses 
were then separately accomplished in each of the 10 data-
sets [36]. Betas were pooled by taking the average of the 
effect sizes of the 10 imputed datasets. The pooled standard 
errors and respective 95% Confidence Intervals (CI) were 
then calculated by using Rubin’s rules [37]. For details of 
the multiple imputation, see supplement Tables S1 and S2. 
The statistical software package of SPSS 24.0 was used for 
the statistical analyses (SPSS Inc., Chicago, Illinois, USA). 
For all the analyses except the effect-modification analysis, 
p values of < 0.05 were considered statistically significant.
Results
Population Characteristics
Baseline characteristics are presented for the total popula-
tion, LD users and non-users (Table 1) and baseline char-
acteristics before and after multiple imputation are shown 
in Table  S2. The median age, on the DXA scan date, 
was 65.0 years [57.0–99.0 IQR] for the total population 
(n = 6990). Of the total population, 7.8% (n = 543) ever used 
LD from baseline till the DXA scan with a mean duration of 
51.2 days (325.1 SD). The median age of the 543 LD users 
was 77.0 years [52.0–99.0 IQR] and 64.0 years [51.0–97.0 
IQR] for the LD non-users (Table 1).
The median serum 25(OH)D level of the LD users 
was 42.3 nmol/L [28.8–62.3 IQR] and for LD non-users, 
55.4  nmol/l [37.2–76.7 IQR]. LD users showed a sig-
nificantly lower serum 25(OH)D level than non-users 
(p < 0.001). The mean dietary calcium intake of the LD users 
was 1189 mg/day (394 SD) and 1121 mg/day (394 SD) for 
LD non-users. Results of the linear regression analysis of 
LD use and indices of bone health are shown in Table 2 and 
discussed below.
Loop Diuretics and LS‑TBS
Compared to LD never-use, current-use of LD was only 
associated with LS-TBS in the crude model (β = − 0.018, 
95% CI − 0.034; − 0.001) and past-use of LD was associ-
ated with lower LS-TBS, in model 1 (β = − 0.031, 95% CI 
− 0.044; − 0.017). Adjustment for covariates in model 2 
attenuated the association somewhat whereby the effect size 
was 30% lower. The analysis of categories of the duration 
of LD use among users and LS-TBS showed no significant 
associations (Table 2).
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Table 1  Characteristics total population, users and non-users of LD
*p value < 0.05
a Mean (SD)
b Median (IQR)
% percentage
Total population (n = 6990) LD ever-users (n = 543) LD never-users (n = 6447) p value LD ever- 
versus never-users
Age (years)b 65.0 [57.0–99.0] 77.0 [52.0–99.0] 64.0 [51.0–97.0] < 0.001*
Sex (%women) 3985 (57.0) 309 (56.9) 3675 (57.0) 0.92
BMI (kg/cm2)a 27.6 (4.1) 28.9 (4.7) 27.5 (4.7) 0.002*
Cohort (%) < 0.001*
 RS-I 2799 (40.0) 437 (80.5) 2360 (36.6)
 RS-II 980 (14.0) 62 (11.4) 918 (14.2)
 RS-III 3211 (46.0) 44 (8.1) 3167 (49.1)
Loop diuretics use (%ever use) 543 (7.8) 543 (100) 0 NA
Duration (days)a NA 194 [40–893] 0
25(OH)D (nmol/l)b 54.4 [36.5–76.0] 42.3 [28.8–62.3] 55.4 [37.2–76.7] < 0.001*
Cutoff (%) < 0.001*
 < 50 nmol/L 2580 (44.2) 247 (45.5) 2333 (36.2) 0.41
 > 50 nmol/L 3257 (55.8) 156 (28.7) 3101 (48.1)
Season measurement (%)
 Spring 1928 (27.6) 147 (27.0) 1854 (28.8)
 Summer 1143 (16.4) 82 (15.1) 1107 (17.2)
 Autumn 2219 (31.7) 177 (32.5) 2126 (33.0)
 Winter 1432 (20.5) 138 (25.4) 1360 (21.0)
Dietary calcium intake (mg/day)a 1126.5 (388.9) 1189.2 (394.1) 1120.8 (394.1) 0.81
 Tertiles (%)
  < 950.0 mg/day 1691 (24.2) 103 (19.0) 1588 (24.6)
  950–1200 mg/day 1504 (21.5) 120 (22.1) 1384 (21.5)
  > 1200 mg/day 1795 (25.7) 186 (34.3) 2609 (25.0)
Lumbar spine  TBSa 1.24 (0.13) 1.17 (0.12) 1.25 (0.12) 0.32
Femoral neck bone mass density (g/
cm2)a
0.91 (0.15) 0.86 (0.15) 0.91 (0.15) 0.98
Lumbar spine bone mass density (g/
cm2)a
1.14 (0.21) 1.15 (0.22) 1.14 (0.20) 0.40
Smoking (%)
 Never smoker 2080 (29.8) 157 (28.9) 1921 (29.8) 0.003*
 Current smoker 1358 (19.4) 58 (10.6) 1302 (20.2)
 Former, non-smoker 3506 (50.2) 319 (58.8) 3185 (49.4)
Pack-yearsa 9.4 (18.6) 20.3 (28.0) 8.5 (28.0) < 0.001*
Education category (%)
 Low education 3575 (51.6) 319 (58.7) 3256 (50.9) < 0.001*
 Higher education 3353 (48.4) 219 (40.3) 3134 (49.1)
Alcohol intake (g/day)b 7.3 [0.8–20.0] 3.1 [0.1–15.7] 7.9 [0.9–20.0] 0.11
PA (MET h/week)b 70.5 [39.4–103.9] 70.8 [47.6–100.1] 70.4 [38.5–104.4] 0.84
Energy intake (kcal/day)a 2176.6 (710.2) 1956.9 (533.8) 2195.2 (533.8) < 0.001*
Comorbidities (%yes) 1112 (15.9) 150 (27.6) 963 (14.9) < 0.001*
CHD 315 (4.5) 69 (12.7) 246 (3.8)
Stroke 129 (1.8) 13 (2.4) 116 (1.8)
DM 790 (11.3) 98 (18.0) 691 (10.7)
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Loop Diuretics and LS‑BMD
Current-use of LD in 210 participants was associated with 
significantly higher LS-BMD compared to never-use of LD 
in the crude model (β = 0.037, 95% CI 0.010; 0.065). Past-
use of LD was associated with higher LS-BMD compared 
to never-use of LD in the crude model, model 2 and fully 
adjusted model (model 3) (β = 0.048, 95% CI 0.026; 0.071, 
β = 0.029, 95% CI 0.006; 0.052 and β = 0.038, 95% CI 0.016; 
0.060). In the analyses of the duration of LD use, current-
use of LD between 121 and 365 days showed a significantly 
higher LS-BMD in fully adjusted model (β = 0.075, 95% CI 
0.007; 0.143 Table 2).
Loop Diuretics and FN‑BMD
LD current-users showed no significant association with FN-
BMD compared to never-use of LD. However, past-use of 
LD showed a significantly higher FN-BMD only in the crude 
model (β = 0.016, 95% CI 0.001; 0.031, Table 2).
Additional adjustment for serum vitamin D, season of 
blood collection of vitamin D, serum calcium, magnesium 
and sodium did not change the results (data not shown).
Furthermore, we evaluated the association between LD 
and LS-TBS, LS-BMD and FN-BMD by sex and found 
no evidence that the association between LD and LS-TBS 
was significantly different according to sex (P-interac-
tion = 0.83). However, the association between LD and 
Table 2  Linear regression of the use of LD and FN-BMD and LS-TBS in RS-I-4, RS-II-2 & RS-III-1
Model 1: sex, age, cohort. Model 2: additional adjusted for BMI, alcohol, smoking, SES, PA and comorbidities (for duration of LD use addi-
tional adjusted for past-users). Model 3: + LS-TBS (for the analysis of FN-BMD)/FN-BMD and LS-BMD (for the analysis of LS-TBS)
*p < 0.05
a Standardized according to sex by residual method
b Past-users depicted in the rows above
Model 1 Model 2 Model 3
β (95%CI) β (95%CI) β (95%CI)
LS-TBS (6476)a
LD never-use (5972) Reference Reference Reference
LD past-use (n = 310) − 0.031 [− 0.044; − 0.017]* − 0.019 [− 0.033; − 0.006]* − 0.025 [− 0.038; − 0.012]*
LD current-use (n = 194) − 0.018 [− 0.034; − 0.001]* − 0.011 [− 0.028; 0.006] − 0.015 [− 0.032; 0.002]
Duration of LD-use categoriesb
Never-users (n = 5972) Reference Reference Reference
Current-users 1–120 days (n = 37) − 0.008 [− 0.027; 0.011] − 0.0005 [− 0.043; 0.042] − 0.003 [− 0.044; 0.039]
Current-users 121–365 days (n = 27) − 0.026 [− 0.048; 0.003] − 0.026 [− 0.070; 0.018] − 0.041 [− 0.084; 0.002]
Current-users > 365 days (n = 310) − 0.019 [− 0.039; 0.001] − 0.010 [− 0.031; 0.010] − 0.013 [− 0.032; 0.007]
LS-BMD (n = 6677)
LD never-use (6146) Reference Reference Reference
LD past-use (n = 321) 0.048 [0.026; 0.071]* 0.029 [0.006; 0.052]* 0.038 [0.016; 0.060]*
LD current-use (n = 210) 0.037 [0.010; 0.065]* 0.021 [− 0.008; 0.050] 0.025 [− 0.003; 0.052]
Duration of LD-use categoriesb
Never-users (n = 6146) Reference Reference Reference
Current-users 1–120 days (n = 41) 0.020 [− 0.040; 0.081] 0.012 [− 0.059; 0.083] 0.014 [− 0.054; 0.082]
Current-users 121–365 days (n = 32) 0.072 [0.004; 0.140]* 0.068 [− 0.003; 0.139] 0.075 [0.007; 0.143]*
Current-users > 365 days (n = 137) 0.034 [0.0004; 0.068]* 0.012 [− 0.022; 0.047] 0.016 [− 0.017; 0.049]
FN-BMD (n = 6908)
LD never-use (6376) Reference Reference Reference
LD past-use (n = 319) 0.016 [0.001; 0.031]* 0.006 [− 0.009; 0.021] 0.010 [− 0.005; 0.025]
LD current-use (n = 213) 0.006 [− 0.012; 0.024] − 0.006 [− 0.025; 0.013] − 0.006 [− 0.024; 0.013]
Duration of LD-use categoriesb
Never-users (n = 6376) Reference Reference Reference
Current-users 1–120 days (n = 44) 0.020 [− 0.019; 0.058] 0.024 [− 0.021; 0.069] 0.021 [− 0.025; 0.067]
Current-users 121–365 days (n = 32) 0.035 [− 0.011; 0.080] 0.019 [− 0.028; 0.066] 0.023 [− 0.023; 0.069]
Current-users > 365 days (n = 137) − 0.005 [− 0.027; 0.018] − 0.019 [− 0.042; 0.003] − 0.018 [− 0.040; 0.004]
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LS-BMD and FN-BMD was significantly different accord-
ing to sex (P-interaction for both = 0.04) (Supplemental 
table S3).
Serum 25(OH)D Level and Dietary Calcium Intake 
in the Association of the Use of Loop Diuretics 
and FN‑BMD, LS‑BMD and LS‑TBS
Effect-modification analyses of serum 25(OH)D level and 
dietary calcium intake in the association between LD use 
on FN-BMD and LS-TBS are shown in Tables 3 and 4. P 
value for interaction terms varied from 0.04 to 0.99. Serum 
25(OH)D level was an effect modifier in the association 
between LD use and LS-TBS (P for interaction = 0.04). 
After stratification in model 2, the group of serum 25(OH)
D level ≥ 50 nmol/L showed a significantly lower LS-TBS 
compared to serum 25(OH)D ≤ 20 nmol/L and between 
20 and 50 nmol/L for LD past-use (β = − 0.036, 95% CI 
− 0.060; − 0.013 vs. β = − 0.012, 95% CI − 0.036; 0.013 and 
β = − 0.031, 95% CI − 0.096; 0.034, respectively, Table 3).
There was no effect modification by serum 25(OH)D 
level on the association between LD use and FN-BMD and 
LS-BMD (Table 3). After stratification, for the analysis of 
the association between LD and LS-BMD, participants with 
serum 25(OH)D level between 20 and 50 nmol/L had a sig-
nificantly higher LS-BMD compared to participants with 
serum 25(OH)D level ≤ 20 and ≥ 50 nmol/l for LD current-
use; however, there was no significant interaction (P for 
interaction = 0.30) (Table 3).
No significant effect modification by dietary calcium 
intake was observed on the association between use of LD 
and FN-BMD, LS-BMD and LS-TBS (Table 4). After strat-
ification of dietary calcium intake in categories of intake 
≤ 950, 950–1200 and ≥ 1200 mg/day, no significant asso-
ciations were found with FN-BMD, LS-BMD and LS-TBS 
(Table 4).
Discussion
In this study, we observed a modest increase in BMD of 
the lumbar spine and a modest decrease in TBS in LD past-
users, and therefore our study conclude that, if any, LD use 
does not have a strong association with bone health, in a 
population with a high calcium intake. Furthermore, this 
study found effect modification by serum 25(OH)D level 
in the association between LD and LS-TBS. However, after 
stratification on serum 25(OH)D, no consistent findings were 
Table 3  Linear regression of LD use (yes/no) on FN-BMD and LS-TBS for 25(OH)D level in categories (≤ 20, 20–50 and ≥ 50 nmol/l) in model 
2
a Standardized according to sex by residual method
*p < 0.05; **p < 0.10
25(OH)D ≤20 nmol/l (n = 302) 25(OH)D 20–50 nmol/l (n = 2240) 25(OH)D ≥50 nmol/l
(n = 3225)
p value 
interaction 
termβ (95%CI) β (95%CI) β (95%CI)
LS-TBS (6476)a
LD never-use Reference Reference Reference 0.04**
LD past-use (n = 310) − 0.012 [− 0.036; 0.013] − 0.031 [− 0.096; 0.034] − 0.036 [− 0.060; − 0.013]*
LD current-use (n = 194) 0.001 [− 0.036; 0.039] − 0.029 [− 0.099; 0.041] − 0.014 [− 0.046; 0.017]
25(OH)D ≤20 nmol/l (n = 287) 25(OH)D 20–50 nmol/l (n = 2146) 25(OH)D ≥50 nmol/l
(n = 3108)
p value 
interaction 
termβ (95%CI) β (95%CI) β (95%CI)
LS-BMD (n = 6677)
LD never-use Reference Reference Reference 0.30
LD past-use (n = 321) 0.079 [− 0.054; 0.148] 0.003 [− 0.034; 0.041] 0.038 [− 0.003; 0.080]
LD current-use (n = 210) − 0.052 [− 0.157; 0.053] 0.044 [0.002; 0.087]* 0.039 [− 0.016; 0.095]
25(OH)D ≤20 nmol/l (n = 267) 25(OH)D 20–50 nmol/l (n = 2054) 25(OH)D ≥50 nmol/l
(n = 3056)
p value 
interaction 
term
β (95%CI) β (95%CI) β (95%CI)
FN-BMD (n = 6908)
LD never-use Reference Reference Reference 0.13
LD past-use (n = 319) 0.027 [− 0.037; 0.092] − 0.006 [− 0.031; 0.019] 0.008 [− 0.020; 0.036]
LD current-use (n = 213) − 0.022 [− 0.089; 0.045] − 0.004 [− 0.031; 0.023] 0.015 [− 0.021; 0.051]
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found in the association between LD use and bone outcomes, 
suggesting no strong modifying effect of serum 25(OH)D on 
these associations. Additionally, no effect modification was 
found by dietary calcium intake.
In our study, current LD use showed a negative associa-
tion with LS-TBS, however not significant.
In contrast to the findings of the association between LD 
and LS-BMD, we found that a history of LD was associ-
ated with a decreased LS-TBS if LD was used in the past. 
To our knowledge, there have been no studies on LD use 
and LS-TBS. TBS is a measurement related to bone micro-
architecture which provides skeletal information that is not 
captured from the standard BMD measurements [31]. Also, 
TBS might be an appropriate measure to study in regard to 
lifestyle factors that are adaptable, such as dietary intake 
[31, 32]. Other studies have reported lower TBS among 
individuals with primary hyperparathyroidism [38]. And as 
mentioned, LDs increase the plasma PTH and 1.25(OH)2D 
levels as a result of increased renal calcium losses [11]. 
Thus, a possible explanation for our finding is that LS-TBS 
may be decreased by secondary hyperparathyroidism caused 
by long-time LD use [13, 39]. However, we could not con-
firm this possible pathway in our current study, since we do 
not have the availability of serum PTH. Other explanation 
for the opposite direction between BMD and TBS is due to 
potential residual confounding (i.e. body composition and 
health status) in the association between LD and TBS. Fur-
ther studies are needed to explore the association between 
LD and overall bone health, especially TBS.
Additionally, LD use was not associated with a lower 
BMD. In contrast, it has been shown that LD increases renal 
calcium excretion [8–11], with a potential negative effect on 
BMD [10, 13, 38]. We expected that LD use would result 
in a lower FN-BMD and LS-BMD, because treatment with 
LD may induce secondary hyperparathyroidism with raised 
bone resorption resulting in a lower BMD [39, 40]. This 
was, however, not confirmed by our findings. Current-use 
of LD showed a non-significant negative association with 
FN-BMD and a non-significant positive association with LS-
BMD. Furthermore, the study of Rejnmark et al. in 2005 
Table 4  Linear regression of LD use (yes/no) on FN-BMD and LS-TBS for dietary calcium intake categories (≤ 950, 950–1200 and ≥ 1200 mg/
day) in model 2
*p  <  0.05
a Standardized according to sex by residual method
Dietary calcium intake 
≤ 950 mg/day (n = 1822)
Dietary calcium intake
950–1,200 mg/day 
(n = 1600)
Dietary calcium intake
≥ 1200 mg/day (n = 1875)
p value interaction term
β (95%CI) β (95%CI) β (95%CI)
LS-TBS (6476)a
LD never-use Reference Reference Reference 0.58
LD past-use (n = 310) (yes/
no)
− 0.018 [− 0.047; 0.010] − 0.022 [− 0.050; 0.005] − 0.015 [− 0.037; 0.007]
LD current-use (n = 194) 
(yes/no)
− 0.009 [− 0.044; 0.025] 0.007 [− 0.028; 0.043] − 0.015 [− 0.043; 0.013]
Dietary calcium intake 
≤ 950 mg/day (n = 1732)
Dietary calcium intake
950–1200 mg/day (n = 1548)
Dietary calcium intake
≥ 1200 mg/day (n = 1838)
p value interaction term
β (95%CI) β (95%CI) β (95%CI)
LS-BMD (n = 6677)
LD never-use Reference Reference Reference 0.87
LD past-use (n = 321) (yes/
no)
0.017 [− 0.034; 0.068] 0.039 [− 0.008; 0.086] 0.026 [− 0.012; 0.063]
LD current-use (n = 210) 
(yes/no)
0.038 [− 0.023; 0.100] 0.045 [− 0.016; 0.106] 0.016 [− 0.031; 0.064]
Dietary calcium intake 
≤ 950 mg/day (n = 1695)
Dietary calcium intake
950–1200 mg/day (n = 1509)
Dietary calcium intake
≥ 1200 mg/day (n = 1771)
p value interaction term
β (95%CI) β (95%CI) β (95%CI)
FN-BMD (n = 6908)
LD never-use Reference Reference Reference 0.99
LD past-use (n = 319) (yes/
no)
0.001 [− 0.032; 0.034] 0.087 [− 0.023; 0.039] 0.008 [− 0.017; 0.034]
LD current-use (n = 213) 
(yes/no)
− 0.003 [− 0.043; 0.037] 0.024 [− 0.015; 0.064] − 0.025 [− 0.057; 0.007]
Do Vitamin D Level and Dietary Calcium Intake Modify the Association Between Loop Diuretics…
1 3
showed also a non-significantly higher LS-BMD for the 
group with LD (who had been treated with a LD for at least 
2 years prior to inclusion in the study), compared with non-
users [38]. Another study of Rejnmark et al. in 2006 showed 
a decrease in BMD for the LD users compared to placebo 
treated for 1 year. The effect was however weakened after 
6 months, end of treatment. Unfortunately, we cannot con-
firm this result in our study. In our analysis of the associa-
tion between the duration of LD and FN-BMD, we found a 
positive association for LD use between 1 and 365 days and 
a negative association with FN-BMD for longer use of LD 
(> 365 days) compared to never-users of LD; nevertheless, 
this was not significant. Also we found an increase in LS-
BMD when LD was used for 121–365 days. This suggests 
that LD use might be weakly associated with higher BMD 
but only for a short time period.
Some studies have shown differences in vitamin D level 
according to LD use. In line with our results, there is evi-
dence that LD users have a lower serum 25(OH)D level than 
non-users [34] and the inverse association between LD use 
and serum 25(OH)D level has been reported before [16]. To 
the best of our knowledge, information about the effect mod-
ification by serum 25(OH)D level on the association between 
LD use and FN-BMD and LS-TBS as bone health param-
eters has not been reported earlier. In our study, stratified 
analyses did not show consistent patterns and the differences 
were not statistically significantly different between cut-offs 
of serum 25(OH)D level. However, we found evidence for 
potential effect modification (P-interaction < 0.10) by serum 
25(OH)D level for the association of LD past-use and LS-
TBS. Stratified analyses showed a slightly stronger inverse 
association between past LD use and LS-TBS in those with 
serum 25(OH)D level ≤ 20; however, the association was 
not significant in strata of serum 25(OH)D level between 
20–50 and above 50 nmol/L. This finding may imply that 
past-use of LD may have affected LS-TBS which can have a 
higher impact in those with extremely low 25(OH)D levels. 
However, because this effect modification was not further 
confirmed by other categories of LD use, further replication 
is needed. Moreover, even though we adjusted our analy-
sis for body fat mass, reduced vitamin D levels may still 
be confounded by other measures of body composition and 
health status.
Our initial hypothesis was that an adequate serum 25(OH)
D level and dietary calcium intake would counteract the 
potential adverse effects of LD on bone health. In contrast, 
we found no consistent significant differences between cat-
egories of dietary calcium intake, in the association between 
LD and FN-BMD, LS-BMD and LS-TBS. Thus, given that 
LD increases the renal excretion of calcium [40], the effects 
of LD on bone health showed unexpected results. This is 
in contrast with earlier studies, showing that a higher die-
tary intake of calcium prevented the expected decrease of 
FN-BMD in LD users [38, 41, 42]. Potentially, the lack of 
calcium modifying the association between LD and bone 
health in our study may result from the fact that in our study 
calcium intake was higher than in other studies.
Strengths and Limitations
A strength in our study is the availability of data on dietary 
intake of calcium, serum 25(OH)D level and LD use, and 
the different indices of bone health (i.e. FN-BMD as well as 
LS-BMD and LS-TBS). Our study also adds data to the quite 
unexplored field of nutrient–drug interactions in a popula-
tion of community-dwelling older persons, who are at risk of 
musculoskeletal diseases, malnutrition and consequences of 
polypharmacy. However, some limitations need to be taken 
into account when interpreting our results. These include 
the observational study design and potential residual con-
founding (for example, underlying disease), which prevents 
us from drawing conclusions regarding causality and the 
direction of the effect size of the association. Furthermore, 
as all our analyses were hypothesis-based, we did not adjust 
for multiple comparisons. With regard to possible type I 
errors, stringent interpretation of p values should be made 
with caution. Likewise, potential misclassification of LD 
use using pharmacy records may occur because data regard-
ing actual compliance was lacking. Also, dietary calcium 
intake was assessed using self-reported dietary assessment, 
which is subject to bias and measurement error. Also, dietary 
intake was measured only once (at baseline) and as a result 
we were unable to account for differences in dietary habits 
over time (e.g. due to disease or medication use). Moreover, 
the complete data on calcium or vitamin D supplement use 
was not available, which could lead to an underestimation 
of dietary intake. In addition, vitamin D and calcium pre-
scriptions were not analysed as exposure variable because 
of confounding by indication. Also, we did not have a com-
prehensive assessment of calcium homeostasis. For exam-
ple, the free calcium concentration in plasma is strongly 
controlled through a complicated physiological system 
including the interaction of calciotropic hormones such as 
PTH and 1,25(OH)D and only in extreme situations will the 
serum calcium concentration deflect from the normal range 
[14]. Since we did not have the availability of serum PTH, 
we could not investigate potential pathways between the use 
of LD and calcium intake and vitamin D level. Finally, our 
result of inconsistent effect modification by serum 25(OH)
D and dietary calcium intake on the associations between 
LD and the parameters of bone health could be explained by 
managing the parathyroid hormones (PTH) and 1.25 (OH)D 
that maintain calcium homeostasis, especially when serum 
calcium is reduced [43].
In conclusion, this study does not support the hypothesis 
that the association between loop diuretic use and indices 
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of bone health is modified by serum 25(OH)D level and 
calcium intake. However, because of polypharmacy effects 
and a higher risk of malnutrition in elderly, further research 
and replication is warranted on nutrient–drug interaction 
on bone health (considering the subjects with osteopenia 
and osteoporosis and people with malnutrition), using other 
biomarkers as PTH and bone turnover markers as well as 
long-term loop diuretic use.
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